Top 10 Strategic Imperatives in the Life Sciences Industry, 2025

Healthcare Top 10 Strategic Imperatives in the Life Sciences Industry, 2025

Key Challenges, Trends, and Changes Transforming the Life Sciences Industry

RELEASE DATE
19-Feb-2025
REGION
Global
Deliverable Type
Market Research
Research Code: PFTF-01-00-00-00
SKU: HC_2025_1314
Available Yes PDF Download
$2,450.00
In stock
SKU
HC_2025_1314

Top 10 Strategic Imperatives in the Life Sciences Industry, 2025
Published on: 19-Feb-2025 | SKU: HC_2025_1314

Need more details?
$2,450.00
DownloadLink
Need more details?

Owing to constant developments and challenges in the life sciences industry, stakeholders must continue to be adaptable, innovative, and competitive to thrive. Industry leaders must reconsider their strategic positions annually by understanding the main forces behind the transformation, including potential, challenges, and drivers.

This analysis explores the strategic imperatives shaping and transforming the life sciences industry. They are as follows:
SaaS evolution provides adaptive intelligence for laboratories
CDMOs augment competencies in new modalities, and digital transformation delivers end-to-end partnerships
Expanding direct-to-consumer (DTC) genetic testing beyond ancestry testing to multi-pathogenic STIs
Uncertainty about trade wars disrupts pharmaceutical supply chains
Decentralized clinical trials (DCTs) boost efficiency for CGTs and rare disorders
Next-generation sequencing (NGS) and liquid biopsy revolutionize oncology diagnostics
Failed clinical trials and shifting market conditions setback biotech innovation
ESG initiatives climb to the top of CEOs' strategic priorities
Real-world insight (RWI) emerges as a strategic compass point to reimagine commercial strategies
CRISPR technology advances biologics R&D

Why is it Increasingly Difficult to Grow?

The Strategic Imperative 8™

Top Transformations Impacting the Growth of the Life Sciences Industry

Key Industry Trends and Challenges

Transformation 1: SaaS Evolution Provides Adaptive Intelligence for Laboratories

Transformation 1: SaaS Evolution Provides Adaptive Intelligence for Laboratories (continued)

Transformation 2: CDMOs Augment Competencies in New Modalities, and Digital Transformation Delivers End-to-End Partnerships

Transformation 2: CDMOs Augment Competencies in New Modalities, and Digital Transformation Delivers End-to-End Partnerships (continued)

Transformation 3: Expanding Direct-to-Consumer (DTC) Genetic Testing Beyond Ancestry Testing to Multi-pathogenic STIs

Transformation 3: Expanding DTC Genetic Testing Beyond Ancestry Testing to Multi-pathogenic STIs (continued)

Transformation 4: Uncertainty About Trade Wars Disrupts Pharmaceutical Supply Chains

Transformation 4: Uncertainty About Trade Wars Disrupts Pharmaceutical Supply Chains (continued)

Transformation 5: Decentralized Clinical Trials (DCTs) Boosting Efficiency for CGTs and Rare Disorders

Transformation 5: DCTs Boosting Efficiency for CGTs and Rare Disorders (continued)

Transformation 6: Next-generation Sequencing (NGS) and Liquid Biopsy Revolutionize Oncology Diagnostics

Transformation 6: NGS and Liquid Biopsy Revolutionize Oncology Diagnostics (continued)

Transformation 7: Failed Clinical Trials and Shifting Market Conditions Setback Biotech Innovation

Transformation 7: Failed Clinical Trials and Shifting Market Conditions Setback Biotech Innovation (continued)

Transformation 8: ESG Initiatives Climb to the Top of CEOs' Strategic Priorities

Transformation 8: ESG Initiatives Climb to the Top of CEOs' Strategic Priorities (continued)

Transformation 9: Real-world Insight (RWI) Emerges as a Strategic Compass Point to Reimagine Commercial Strategies

Transformation 9: RWI Emerges as a Strategic Compass Point to Reimagine Commercial Strategies (continued)

Transformation 10: CRISPR Technology Advances Biologics R&D

Transformation 10: CRISPR Technology Advances Biologics R&D (continued)

Frost & Sullivan Analytics Perspectives

Benefits and Impacts of Growth Opportunities

Next Steps

Legal Disclaimer

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

Owing to constant developments and challenges in the life sciences industry, stakeholders must continue to be adaptable, innovative, and competitive to thrive. Industry leaders must reconsider their strategic positions annually by understanding the main forces behind the transformation, including potential, challenges, and drivers. This analysis explores the strategic imperatives shaping and transforming the life sciences industry. They are as follows: SaaS evolution provides adaptive intelligence for laboratories CDMOs augment competencies in new modalities, and digital transformation delivers end-to-end partnerships Expanding direct-to-consumer (DTC) genetic testing beyond ancestry testing to multi-pathogenic STIs Uncertainty about trade wars disrupts pharmaceutical supply chains Decentralized clinical trials (DCTs) boost efficiency for CGTs and rare disorders Next-generation sequencing (NGS) and liquid biopsy revolutionize oncology diagnostics Failed clinical trials and shifting market conditions setback biotech innovation ESG initiatives climb to the top of CEOs' strategic priorities Real-world insight (RWI) emerges as a strategic compass point to reimagine commercial strategies CRISPR technology advances biologics R&D
More Information
Deliverable Type Market Research
Author Chandni Hussain
Industries Healthcare
No Index No
Is Prebook No
Keyword 1 Life sciences market trends
Keyword 2 Precision medicine growth
Keyword 3 Life sciences regulations
Podcast No
WIP Number PFTF-01-00-00-00